Project Details
Description
A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination with Docetaxel plus Prednisone in Metastatic Castration Resistant Prostate Cancer
Status | Finished |
---|---|
Effective start/end date | 4/1/18 → 3/30/22 |
Funding
- PROSTATE CANCER CLINTRIAL CONSORTIUM LLC
- NOVARTIS PHARMACEUTICALS CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.